Product Information

GVOKE HYPOPEN 1-PK 1 MG/0.2 ML is a brand product labeled by Xeris Pharmaceuticals, Inc., priced at $1603.2800 per ML under NDC 72065012111. Its NADAC has been published 215 times since May 18, 2022.

GVOKE HYPOPEN 1-PK 1 MG/0.2 ML

glucagon injection, solution
$1603.2800per ML

Strength

1 mg/.2mL

NDC

72065012111

Classification

Brand

Dosage Form

INJECTION, SOLUTION

Route

SUBCUTANEOUS

Last Updated

6/17/2026

Active Ingredients

GLUCAGON

Approval Type

New Drug (NDA)

FDA Application

NDA212097

On Market Since

9/10/2019

Pharmacological Classes

Antihypoglycemic Agent
Decreased GI Motility
Decreased GI Smooth Muscle Tone
Decreased Glycolysis
Gastrointestinal Motility Inhibitor
Increased Gluconeogenesis
Increased Glycogenolysis

Price Statistics

The NADAC for GVOKE HYPOPEN 1-PK 1 MG/0.2 ML has been published 215 times since May 18, 2022, and over the history we have for it it has risen 12.3%. The table below summarizes its recorded NADAC range and movement.

Current price$1603.2800 per ML
All-time high$1603.2800 (Jun 24, 2026)
All-time low$1427.3900 (May 18, 2022)
52-week high$1603.2800
52-week low$1553.4469
Median price$1515.4017
Average price$1507.9294
Largest weekly change+3.0% (Feb 15, 2023)
Weeks tracked215
Tracking sinceMay 18, 2022

Price History

1W

0.0%

1M

+0.1%

3M

+0.1%

6M

+3.0%

1Y

+3.0%

3Y

+9.0%

5Y

N/A

All

+12.3%

Generic Alternatives

The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 0%

1 alternative • Same active ingredient

Frequently asked questions

What is the NADAC price of GVOKE HYPOPEN 1-PK 1 MG/0.2 ML?

The current National Average Drug Acquisition Cost (NADAC) for GVOKE HYPOPEN 1-PK 1 MG/0.2 ML, manufactured by Xeris Pharmaceuticals, Inc., is $1603.2800 per ML (NDC 72065012111), effective Jun 24, 2026.

How has the price of GVOKE HYPOPEN 1-PK 1 MG/0.2 ML changed over time?

Over the history we have for it, the NADAC for GVOKE HYPOPEN 1-PK 1 MG/0.2 ML has risen 12.3%. It has been tracked across 215 weekly CMS publications since May 18, 2022.

What are the highest and lowest recorded NADAC prices for GVOKE HYPOPEN 1-PK 1 MG/0.2 ML?

Since May 18, 2022, the NADAC for GVOKE HYPOPEN 1-PK 1 MG/0.2 ML has ranged from a low of $1427.3900 (May 18, 2022) to a high of $1603.2800 (Jun 24, 2026), with a median of $1515.4017 per ML.

Are there cheaper alternatives to GVOKE HYPOPEN 1-PK 1 MG/0.2 ML?

Yes. 1 NADAC-published product shares the same active ingredient, strength, and dosage form. The lowest-priced option, GVOKE HYPOPEN 2-PK 1 MG/0.2 ML, is $1597.9517 per ML — about 0% below GVOKE HYPOPEN 1-PK 1 MG/0.2 ML.

Who manufactures GVOKE HYPOPEN 1-PK 1 MG/0.2 ML?

GVOKE HYPOPEN 1-PK 1 MG/0.2 ML (NDC 72065012111) is labeled by Xeris Pharmaceuticals, Inc., and CMS classifies it as a brand product.